BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 19919943)

  • 1. Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis.
    van Eijk IC; Tushuizen ME; Sturk A; Dijkmans BA; Boers M; Voskuyl AE; Diamant M; Wolbink GJ; Nieuwland R; Nurmohamed MT
    Ann Rheum Dis; 2010 Jul; 69(7):1378-82. PubMed ID: 19919943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals.
    Biró E; Nieuwland R; Tak PP; Pronk LM; Schaap MC; Sturk A; Hack CE
    Ann Rheum Dis; 2007 Aug; 66(8):1085-92. PubMed ID: 17261534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation.
    Nielsen CT; Østergaard O; Stener L; Iversen LV; Truedsson L; Gullstrand B; Jacobsen S; Heegaard NH
    Arthritis Rheum; 2012 Apr; 64(4):1227-36. PubMed ID: 22238051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activation.
    van der Zee PM; Biró E; Trouw LA; Ko Y; de Winter RJ; Hack CE; Sturk A; Nieuwland R
    Clin Immunol; 2010 Jun; 135(3):490-5. PubMed ID: 20138585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset.
    Mullazehi M; Mathsson L; Lampa J; Rönnelid J
    Ann Rheum Dis; 2007 Apr; 66(4):537-41. PubMed ID: 17040962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein.
    Molenaar ET; Voskuyl AE; Familian A; van Mierlo GJ; Dijkmans BA; Hack CE
    Arthritis Rheum; 2001 May; 44(5):997-1002. PubMed ID: 11352263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of antirheumatic drugs on circulating immune complexes in rheumatoid arthritis.
    Forster PJ; McConkey B
    Q J Med; 1986 Jan; 58(225):29-42. PubMed ID: 2871585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis.
    Syngle A; Vohra K; Kaur L; Sharma S
    Scand J Rheumatol; 2009; 38(1):15-22. PubMed ID: 18766955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
    Familian A; Voskuyl AE; van Mierlo GJ; Heijst HA; Twisk JW; Dijkmans BA; Hack CE
    Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis.
    Syngle A; Vohra K; Garg N; Kaur L; Chand P
    Int J Rheum Dis; 2012 Feb; 15(1):45-55. PubMed ID: 22324946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
    J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis.
    Knijff-Dutmer EA; Koerts J; Nieuwland R; Kalsbeek-Batenburg EM; van de Laar MA
    Arthritis Rheum; 2002 Jun; 46(6):1498-503. PubMed ID: 12115179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis.
    Valle Y; Ledezma-Lozano IY; Torres-Carrillo N; Padilla-Gutiérrez JR; Navarro-Hernández RE; Vázquez-Del Mercado M; Palafox-Sánchez CA; Armendáriz-Borunda J; Muñoz-Valle JF
    Scand J Rheumatol; 2009; 38(5):332-5. PubMed ID: 19579138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
    Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
    J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment.
    Foster W; Carruthers D; Lip GY; Blann AD
    J Rheumatol; 2010 Apr; 37(4):711-6. PubMed ID: 20156948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum amyloid A in the assessment of early inflammatory arthritis.
    Cunnane G; Grehan S; Geoghegan S; McCormack C; Shields D; Whitehead AS; Bresnihan B; Fitzgerald O
    J Rheumatol; 2000 Jan; 27(1):58-63. PubMed ID: 10648018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.